XML 28 R18.htm IDEA: XBRL DOCUMENT
v3.22.1

SHARE-BASED COMPENSATION | 3 Months Ended
--- | ---
Mar. 27, 2022
Share-based Payment Arrangement [Abstract] |
Share-Based Compensation | SHARE-BASED COMPENSATION Stock Options For the thirteen week periods ended March 27, 2022 and March 28, 2021, the Company recognized $0.1 million of compensation expense from continuing operations related to stock options. Unamortized share-based compensation expense from continuing operations as of March 27, 2022 amounted to $0.7 million which is expected to be recognized over the next 2.2 years. A summary of stock option activity is presented as follows:
| Number of Shares |  | Weighted Average Exercise Price Per Share |  | Weighted Average Remaining Contractual Life |  | Total Intrinsic Value of Awards (in thousands)
Options outstanding at December 26, 2021 | 695,329 |  |  | $ | 16.91 |  |  | 6.7 |  | $ | 665 |
Options outstanding at March 27, 2022 | 695,329 |  |  | $ | 16.91 |  |  | 6.5 |  | $ | 822 |
Options exercisable at December 26, 2021 | 475,765 |  |  | $ | 17.62 |  |  | 5.9 |  | $ | 452 |
Options exercisable at March 27, 2022 | 496,415 |  |  | $ | 17.75 |  |  | 5.7 |  | $ | 595 |
|  | Number of Shares |  | Weighted Average Grant Date Fair Value
Nonvested outstanding at December 26, 2021 |  | 219,564 |  |  | $ | 12.73 |
Nonvested outstanding at March 27, 2022 |  | 198,914 |  |  | $ | 12.73 |
For the thirteen week period ended March 27, 2022, the Company did not issue shares under a cashless exercise. For the thirteen week period ended March 28, 2021, the Company issued 213 shares of common stock upon the cashless exercise of 600 stock options. Restricted Stock For the thirteen week periods ended March 27, 2022 and March 28, 2021, the Company recognized $0.1 million of compensation expense related to restricted stock awards. Unamortized share-based compensation expense as of March 27, 2022 amounted to $0.6 million which is expected to be recognized over the next 2.2 years. A summary of restricted stock activity is presented as follows:
| Number of Shares |  | Weighted Average Grant Date Fair Value
Restricted stock outstanding at December 26, 2021 | 60,844 |  |  | $ | 11.91 |
Issued | 5,795 |  |  | $ | 11.99 |
Vested | (4,828) |  |  | $ | 17.51 |
Restricted stock outstanding at March 27, 2022 | 61,811 |  |  | $ | 11.62 |
Nonvested outstanding at December 26, 2021 | 60,844 |  |  | $ | 11.91 |
Nonvested outstanding at March 27, 2022 | 61,811 |  |  | $ | 11.62 |
The intrinsic value in the tables above is the amount by which the market value of the underlying stock exceeded the exercise price of outstanding options or warrants, before applicable income taxes and represents the amount holders would have realized if all in-the-money options or warrants had been exercised on the last business day of the period indicated. 2020 Employee Stock Purchase Plan (“2020 ESPP”) In November 2020, the Company's shareholders approved the 2020 ESPP. Under the 2020 ESPP, eligible team members of the Company may elect for payroll deductions to purchase shares on each purchase date during an offering period. A total of 250,000 shares of common stock of BGSF, Inc. were initially reserved for issuance pursuant to the 2020 ESPP. For the thirteen week period ended March 27, 2022, the Company issued 14,203 shares of common stock under the ESPP.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration